Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation
Advanced Science · 2025
DOI: 10.1002/advs.202504690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yizhuo Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: COVID-19, Spike Glycoprotein, Coronavirus, SARS-CoV-2, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Complement dysregulation and immune hyperactivation are pivotal factors contributing to the mortality associated with SARS‐CoV‐2 infection. Engineered Antibody‐like proteins (ALPs) targeting the SARS‐CoV‐2 spike protein are engineered to address immune dysregulation in COVID‐19. In this study, Lectifitin‐36 and Lectifitin‐41, two such ALPs, are developed using cDNA display technology. These ALPs demonstrate strong binding affinity for the spike protein and effectively inhibit its interaction with ACE2 and several C‐type lectins, including MBL, DC‐SIGN, and L‐SIGN. Both in vitro and in vivo analyses reveal that Lectifitin‐36 and Lectifitin‐41 suppress complement activation via the lectin pathway, reduce neutrophil extracellular trap (NET) formation, and attenuate hyper‐inflammatory responses. In mouse models, Lectifitin‐36 and Lectifitin‐41 significantly mitigate inflammation, NETosis, and lung tissue damage induced by the spike protein. These results suggest that these ALPs hold promise as therapeutic candidates for alleviating SARS‐CoV‐2‐induced immune dysfunction, with the potential to reduce severe COVID‐19 outcomes and long‐term sequelae. This study underscores the therapeutic potential of targeting spike protein‐mediated immune modulation as an innovative approach to combat COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, 430071, China.
- Institute for Vaccine Research, Animal Bio-Safety Level III Laboratory / Center for Animal Experiment, Wuhan University School of Medicine, Wuhan, 430071, China.
- State Key Laboratory of Virology and Biosafety, Modern Virology Research Center and RNA Institute, College of Life Sciences, Wuhan University, Wuhan, 430071, China.
- Departmant of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430021, China.
ORCID-Profile: Xin Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Bai, C., Hou, K., Zhang, Z., Guo, M., Wang, X., Yang, F., & Liu, X. (2025). Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation. Advanced Science. https://doi.org/10.1002/advs.202504690
Vancouver
Wang Y, Bai C, Hou K, Zhang Z, Guo M, Wang X, et al. Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation. Advanced Science. 2025. doi:10.1002/advs.202504690
BibTeX
@article{Wang2025,
author = {Wang, Yizhuo and Bai, Chenwu and Hou, Kerui and Zhang, Zhen and Guo, Ming and Wang, Xin and Yang, Fan and Liu, Xin},
title = {Engineered Dual‐Function Antibody‐Like Proteins to Combat SARS‐CoV‐2‐Induced Immune Dysregulation and Inflammation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504690}
}
EUVIMED